<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A plasmid DNA vaccine, encoding a truncated form of human CEA fused to a T-helper <z:chebi fb="0" ids="53000">epitope</z:chebi> (CEA66 DNA) was delivered three times intradermally at 2 mg or intramuscularly at 8 mg by Biojector® to patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Prior to the first vaccination, <z:hpo ids='HP_0000001'>all</z:hpo> patients received <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (300 mg/m²) intravenously </plain></SENT>
<SENT sid="2" pm="."><plain>Granulocyte-macrophage colony-stimulating factor (GM-CSF) was administered subcutaneously with each vaccination </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients completed the vaccine schedule </plain></SENT>
<SENT sid="4" pm="."><plain>There were no grade 3 or 4 adverse events (AE) </plain></SENT>
<SENT sid="5" pm="."><plain>The most frequently reported AE grades 1 and 2 were injection site reactions, <z:mp ids='MP_0002899'>fatigue</z:mp>, <z:hpo ids='HP_0002315'>headache</z:hpo>, <z:hpo ids='HP_0002829'>arthralgia</z:hpo>, chest tightness and <z:hpo ids='HP_0003326'>myalgia</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Vaccination with CEA66 DNA in combination with GM-CSF was well tolerated and no signs of <z:hpo ids='HP_0002960'>autoimmunity</z:hpo> have been detected </plain></SENT>
</text></document>